Information Provided By: 
Fly News Breaks for December 15, 2016
RHHBY, PACB
Dec 15, 2016 | 11:00 EDT
Cantor Fitzgerald analyst Bryan Brokmeier said Roche's (RHHBY) termination of its collaboration agreement with Pacific Biosciences is a "significant negative" for the latter, as he was forecasting Roche-generated revenues of $14.3M in 2017 and $27.5M in 2018. Pacific Bio should not lose all of that revenue, since it will now be able to sell into the clinical market or partner with another company, but that will require further investments, said Brokmeier, who has an Overweight rating and $15 price target on the stock.
News For PACB;RHHBY From the Last 2 Days
PACB
Apr 22, 2024 | 09:47 EDT
PACB
Apr 22, 2024 | 04:46 EDT
